Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
- Wound Care
- Drug Discovery
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 260415
University grants a first option to add Improvement to the Patent Rights, only in the fields for which exclusive rights, for six months after Company has been notified of the existence of each such Improvement.
Patent titles include Solid-and Solution-Phase Synthesis of Heparin and Other Glycosaminoglycans;
Synthesis of Oligosaccharides in Solution and on the Solid Support; Linkers for Synthesis of Oligosaccharides on Solid-Support; Protecting Groups Useful in the Synthesis of Polysaccharides, Natural Products, and Combinatorial Libraries; Apparatus and Methods for the Automated Synthesis of Oligosaccharides; Rationally Designed Heparinases Derived from Heparinase I and II; System and Method for Notating Polymers; and, Method for Identifying or Characterizing Properties of Polymeric Units.
The Field Therapeutics shall mean for internal use in the discovery and development of therapeutic compounds; and, the clinical testing, manufacture and sale of therapeutic compounds. This field shall not include the sale of research reagents or of synthesis machines.
The Field Heparinase shall mean all fields of use except for human use of heparinases as therapeutics in pharmaceutical compositions and except for Field Sequencing Machines.
IPSCIO Record ID: 262411
The original agreement patent rights are for Heparin and Masspec for Field all but Machines; for Case 9180 for Field Therapeutics; for Case 9180 Background to enable and only to enable the practice of patent rights Case 9180; and patent rights Heparinase for Field Heparinase.
— Field Enzymes meaning all fields of use, except for use of the enzymes described in the Patent Rights Enzymes as human therapeutics in pharmaceutical compositions and except for Field Sequencing Machines, and,
— Field Research Reagents meaning the making, using and/or selling of enzymes and/or heparinases as reagents for research use by not-for-profit entities.
IPSCIO Record ID: 227291
The heparin assay, antiâ€“factor Xa assay, is designed to measure plasma heparin (UH and LMWH) levels and to monitor anticoagulant therapy. Heparin is a mixture of negatively charged glycosaminoglycans (sulfated mucopolysaccharides) that have anticoagulant properties due to their interaction with the natural anticoagulant antithrombin.
The Diagnostic Field shall mean clinical diagnostics using the Heparinases for in vitro testing of external tissue samples from patients.
Research Reagent Field shall mean research reagent uses of the Heparinases designated for research purposes only, not to be used in humans.
The Therapeutic Field shall mean human use of the Heparinases as therapeutics in pharmaceutical compositions for reversal of anticoagulants, inflammation, reperfusion injury, restenosis and wound healing.
IPSCIO Record ID: 260416
University grants to Licensee a first option to add improvements to the Patent Rights, only in the fields for which exclusive rights are granted.
Heparanase, also known as HPSE, is an enzyme that acts both at the cell-surface and within the extracellular matrix to degrade polymeric heparan sulfate molecules into shorter chain length oligosaccharides.
Licensee is also utilizing our ability to sequence, or analyze the molecular structure of, sugars, to create generic versions of complex sugar-based drugs, or technology-enabled generic products. Through detailed analysis of the molecular structure of complex sugars, our technology provides a more complete understanding of the roles that sugars play in cellular function, disease and drug action. Based on our understanding of complex sugars, Licensee has developed a diversified pipeline of novel discovery and development candidates and near-term product opportunities.
IPSCIO Record ID: 26785
The licensee is a U.S. company.
The term carbohydrate embraces a wide variety of chemical compounds having the general formula (CH.sub.2 O).sub.n, such as monosaccharides, disaccharides, oligosaccharides and polysaccharides. Oligosaccharides are chains composed of saccharide units, which are alternatively known as sugars. These saccharide units can be arranged in any order and the linkage between two saccharide units can occur in any of approximately ten different ways. As a result, the number of different possible stereoisomeric oligosaccharide chains is enormous.
U.S. Patent No. 5,180,674, entitled Saccharide Compositions, Methods and Apparatus for their Synthesis, issued January 19, 1993.
U.S. Patent No. 5,288,637, entitled Apparatus for the Synthesis of Saccharide Compositions, issued February 22, 1994.
U.S. Patent No. 5,583,042, entitled Apparatus for the Synthesis of Saccharide Compositions, issued December 10, 1996.
U.S. Patent No. 5,874,261, entitled Method for the Purification of Glycosyltransferases, issued February 23, 1999.
U.S. Patent No. 6,156,547, entitled Apparatus for the Synthesis of Saccharide Compositions, issued December 5, 2000.
U.S. Patent No. 6,331,418, entitled Saccharide Compositions, Methods and Apparatus for Their Synthesis, issued December 18, 2001.
U.S. Patent No. 6,518,051, entitled Saccharide Compositions, Methods and Apparatus for Their Synthesis, issued February 11, 2003.
IPSCIO Record ID: 4311
The License Agreement provides the Licensee with a non-transferable, worldwide license to use the Licensor's VAST technology, including related patents, patent applications and know-how.
The license is exclusive except in relation to one family of patents in respect of which there is an existing non-exclusive third party license.
Under the Technology License Agreement, the Licensee is subject to development obligations, reporting obligations, sublicense revenue sharing requirements, royalty payments and other obligations.
In that regard, the license agreement does not permit the Licensee to sub-license any of the VAST technology without the Licensor's prior consent.
Trade Mark VAST & Chemoform
6,573,337 & 6,723,843
Protecting and Linking Groups for Organic Synthesis 6,765,089
Protecting Groups for Carbohydrate Synthesis
Combinatorial Libraries of Monosaccharideâ€™s
7,417,129 & 8,093,227
Synthetic Heparin Pentasaccharides
7,541,445 & 8,114,970